If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
90.00    0.00 (0.00%)
Bid:
85.00
Ask:
95.00
Spread: 10.00 (11.765%)
Market Cap: £5.92m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Long Term Contract with NCHCD

12 Oct 2016 07:00

RNS Number : 2818M
Crimson Tide PLC
12 October 2016
 

Crimson Tide PLC

("Crimson Tide" or the 'Company')

Crimson Tide signs long term contract with National Centre for Hereditary Coagulation Disorders (NCHCD)

 

Crimson Tide ﴾TIDE﴿, the AIM‐quoted provider of mpro5 ‐ Smart Mobility as a Service, has entered into a contract with the NCHCD in Ireland, whereby mpro5 will deliver its healthcare solution to patients in the management of treatment for hereditary coagulation disorders, commonly known as haemophilia.

 

The contract value is worth approximately €140,000 in revenue over a term of 36 months, which includes delivery of the mpro5 mobility solution directly to patients. This is the first contract Crimson Tide has signed directly with the NCHCD as previously its solutions were delivered via a third party.

 

Patients at home use mpro5 to scan medication they receive from the hospital. The barcode information is then sent to a central hub for verification of type and date ranges. Confirmation is then returned to the patient, informing them of the medication validity and safe administration.

 

New functionality now improves this process, - including verification of stock levels and expiry date prompts, thereby providing further information to the patient and assisting in reducing stock wastage.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "We are delighted to be able to work directly with the NCHCD in providing patients with hereditary coagulation disorders a solution to manage their use of prescribed pharmaceutical products. This empowers patients to manage their condition and provides the NCHCD with valuable real time information."

 

For further information:

Crimson Tide plc

 

Barrie Whipp/Steve Goodwin 01892 542 444

 

WH Ireland

James Joyce /James Bavister 020 7220 1666

 

Notes to editors

1. Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 ‐ Smart Mobility as a Service (SMaaS). mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

2. Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world‐class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

3. mpro5 is a platform‐agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

4. mpro5 not only helps people improve their day‐to‐day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to listen, share and find the best solution for all mobility needs.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKFLFFQBFEFBD
Date   Source Headline
23rd May 20137:00 amRNSThree New Contract Wins
26th Apr 20137:00 amRNSFinal Results
11th Apr 20137:00 amRNSContract Wins with Associated Newspapers for Metro
9th Apr 201310:08 amRNSHolding(s) in Company
29th Jan 201312:32 pmRNSHolding(s) in Company
13th Nov 20127:00 amRNSContract Win to Develop App for Autism Sufferers
17th Oct 20127:00 amRNSSigned agreement with Microsoft
27th Sep 20127:00 amRNSInterim Results
24th Sep 201212:51 pmRNSHolding(s) in Company
19th Sep 20127:00 amRNSMPRO5 Upgrade and Contract Wins
5th Sep 20127:00 amRNSHolding(s) in Company
13th Aug 201210:49 amRNSAppointment of Director
29th Jun 201211:14 amRNSResult of Meeting
28th Jun 20125:09 pmRNSResult of AGM
21st Jun 20127:00 amRNSContract Extension
7th Jun 20127:00 amRNSContract Win
6th Jun 20127:00 amRNSPosting of Final Accounts and Notice of AGM
16th May 20127:00 amRNSContract Wins
10th May 20127:03 amRNSFinal Results
9th May 201212:35 pmRNSHolding(s) in Company
1st May 20127:00 amRNSCrimson Tide contract with Euro Food Brands
24th Apr 20127:00 amRNSHaemophiliac Home Treatment Update
5th Dec 20114:25 pmRNSDirector/PDMR Shareholding
29th Sep 20117:00 amRNSHalf Yearly Report
12th Sep 20117:00 amRNSPremier Telecoms Agreement
20th Jul 20117:00 amRNSSTRATEGIC PARTNERSHIP WITH CRIMSON TIDE PLC
20th Jul 20117:00 amRNSStrategic Partnership
29th Jun 201112:27 pmRNSResult of AGM
6th Jun 20114:03 pmRNSAnnual Report and Notice of AGM
31st May 20117:54 amRNSTotal Voting Rights
12th May 20117:01 amRNSExercise of option and repayment of debt
12th May 20117:00 amRNSFinal Results
19th Apr 20117:00 amRNSChange of Adviser
16th Feb 201111:59 amRNSHolding(s) in Company
15th Feb 20117:00 amRNSHolding(s) in Company
4th Feb 20117:00 amRNSHolding(s) in Company
31st Jan 20117:00 amRNSContract with Associated Newspapers
17th Jan 20117:00 amRNSIssue of Equity
17th Nov 201011:09 amRNSHolding(s) in Company
14th Oct 20107:00 amRNSIssue of Equity
28th Sep 20107:00 amRNSHalf Yearly Report
31st Aug 20107:01 amRNSCrimson Tide wins first South African Contract
29th Jun 20102:39 pmRNSResult of AGM
2nd Jun 20107:00 amRNSAnnual Financial Report
10th May 20107:00 amRNSFirst Own Brand Mobile Software Product
7th May 20102:50 pmRNSGrant of Options
13th Apr 20107:00 amRNSPreliminary Results
9th Apr 20107:00 amRNSContract Win
7th Apr 20107:00 amRNSTechnology provider for study on ageing
18th Mar 20103:37 pmRNSExtension of Loan Facility

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.